Latest From ValCare Inc.
There’s still money for early-stage innovation despite worries to the contrary, but total dollars for Series A financings remain about one-third fewer than during the high years of the mid-2000s, and investor syndicates are mindful of making those dollars stretch as far as possible. For the 2012 A-List, our ninth, we’ve decided to ask a fundamental question as the life science venture world goes through economic upheaval: does “Series A” mean the same thing, or conjure the same connotations, as it did when the class of 2004 made the first A-List?
Device companies raised a total of $801 million in 2012’s third quarter, an 18% drop from Q2’s $977 million. Approximately $2.6 billion was spent on device acquisitions, exactly $2 billion less than Q2’s total. Diagnostic/research company financings totaled $484 million during Q3 2012, up from last quarter’s $336 million. And while diagnostic/research M&A activity was not as prolific as last quarter, tech transfer deals are seeing a resurgence.
In the third quarter of 2012, start-up companies raised a total of $682 million across all industries, roughly 19% more than in the previous quarter. Of that money, 65% went to biopharmas. Several large molecule-focused companies inked deals during Q3. Four start-ups were acquired – three biopharmas and one medical device company.
START-UP's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- ValCare Inc.
- Senior Management
- Sam Shaolian, CEO
- Contact Info
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.